Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2152PDF: 1710HTML: 382 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2910PDF: 1368HTML: 3574Untitled: 194Untitled: 210Untitled: 182 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
793PDF: 93HTML: 145 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
495PDF: 250HTML: 79 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1064PDF: 1171Suppl. Files: 569HTML: 89 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1229PDF: 1076HTML: 205 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1398HTML: 474PDF: 832 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3806PDF: 1674HTML: 11613Figures Haase: 204 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1987PDF: 726HTML: 688Table1: patient's characteristics: 159Table 2: profile of each patient: 181 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3352PDF: 1976HTML: 7476 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2479HTML: 279PDF: 883 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9123PDF: 6082HTML: 87966Fig.1b: 188Fig.1c: 194Fig.2a: 180Fig.2b: 180Fig.4: 192Fig.2c: 189Fig.3: 187Tab.1: 233Tab.2: 212Tab.3: 192Tab.4: 227Fig1a: 191 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3570PDF: 1196HTML: 5004Incidence age-standardized rates for HL across the Mediterranean basin: 206 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3272PDF: 1714HTML: 1091 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2597PDF: 807HTML: 5223 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3633PDF: 896HTML: 6719 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1563PDF: 1034HTML: 234 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3576PDF: 2505HTML: 1492 -
SOLITARY PLASMACYTOMA
3893PDF: 2191HTML: 1235fIGURES 1,2: 221 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2404PDF: 1013HTML: 154Suppl. Files: 515 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3621PDF: 1651HTML: 2679 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2187PDF: 1597HTML: 312 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3085PDF: 883HTML: 7171Kost Fig1: 189Kost Fig 2: 183Kost Fig3: 180Kost Fig 4: 195Kost Fig5: 190Kost fig 6: 176 -
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2478PDF: 790HTML: 1737 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4009PDF: 1522HTML: 9191Untitled: 283Untitled: 189Untitled: 175Untitled: 167Untitled: 191Untitled: 344 -
-
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2790PDF: 1129HTML: 3288 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4010PDF: 1056HTML: 3601Untitled: 178Cneo. Fig.1: 115Untitled: 106Untitled: 128Untitled: 135 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2826PDF: 1014HTML: 5526







